CN102482325B - 通过抑制微粒的分泌治疗aids或癌症的组合物和方法 - Google Patents

通过抑制微粒的分泌治疗aids或癌症的组合物和方法 Download PDF

Info

Publication number
CN102482325B
CN102482325B CN201080025184.7A CN201080025184A CN102482325B CN 102482325 B CN102482325 B CN 102482325B CN 201080025184 A CN201080025184 A CN 201080025184A CN 102482325 B CN102482325 B CN 102482325B
Authority
CN
China
Prior art keywords
peptide
cells
seq
smrwt
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080025184.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN102482325A (zh
Inventor
文森特·克雷格·邦德
迈克尔·鲍威尔
铭博·黄
赛义德·阿里
安德烈亚·D·雷蒙德
马丁·内维尔·谢尔顿
弗朗索瓦·琼·菲林格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morehouse School of Medicine Inc
Original Assignee
Morehouse School of Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morehouse School of Medicine Inc filed Critical Morehouse School of Medicine Inc
Publication of CN102482325A publication Critical patent/CN102482325A/zh
Application granted granted Critical
Publication of CN102482325B publication Critical patent/CN102482325B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201080025184.7A 2009-06-12 2010-05-21 通过抑制微粒的分泌治疗aids或癌症的组合物和方法 Active CN102482325B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21347109P 2009-06-12 2009-06-12
US61/213,471 2009-06-12
US12/783,829 US8431530B2 (en) 2009-06-12 2010-05-20 Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles
US12/783,829 2010-05-20
PCT/US2010/035698 WO2010144231A2 (en) 2009-06-12 2010-05-21 Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles

Publications (2)

Publication Number Publication Date
CN102482325A CN102482325A (zh) 2012-05-30
CN102482325B true CN102482325B (zh) 2015-01-07

Family

ID=43306940

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080025184.7A Active CN102482325B (zh) 2009-06-12 2010-05-21 通过抑制微粒的分泌治疗aids或癌症的组合物和方法

Country Status (6)

Country Link
US (5) US8431530B2 (enExample)
EP (1) EP2440570B1 (enExample)
JP (1) JP2012529293A (enExample)
CN (1) CN102482325B (enExample)
CA (1) CA2761121A1 (enExample)
WO (1) WO2010144231A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013052058A1 (en) * 2011-10-07 2013-04-11 Morehouse School Of Medicine Antimicrobial compositions and methods of use thereof
US12083158B2 (en) 2011-10-07 2024-09-10 Morehouse School Of Medicine Antibacterial compositions, methods of making and use thereof
US8669226B2 (en) * 2011-10-07 2014-03-11 Morehouse School Of Medicine Antimicrobial compositions and methods of use thereof
EP2790735A4 (en) * 2011-12-13 2015-12-09 Ohio State Innovation Foundation METHODS AND COMPOSITIONS RELATING TO MIR-21 AND MIR-29A, EXOSOME INHIBITION, AND CANCER METASTASIS
US10702581B2 (en) 2015-05-04 2020-07-07 Ilias Biologics Inc. Compositions containing protein loaded exosome and methods for preparing and delivering the same
IL259023B (en) * 2016-09-30 2022-09-01 Cellex Life Sciences Incorporated Compositions containing protein loaded exosomes and methods for preparing same and uses thereof
US10800817B2 (en) 2016-12-19 2020-10-13 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
EP3554638B1 (en) * 2016-12-19 2022-02-02 Morehouse School of Medicine Compositions and methods for treating diseases by inhibiting exosome release
MX2019014265A (es) 2017-06-01 2020-08-03 Compugen Ltd Tratamientos conjuntos triples con anticuerpos.
WO2020081634A2 (en) * 2018-10-16 2020-04-23 George Mason Research Foundation, Inc. Compositions and methods for modulation of extracellular vesicle release and treatment of neurological disorders
US11180534B1 (en) 2021-06-04 2021-11-23 Morehouse School Of Medicine Compositions and methods for treating SARS-CoV-2 infections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
US7476386B1 (en) * 1997-12-03 2009-01-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mixed lipopeptide micelles for inducing an immune response
US7517520B2 (en) * 2003-03-26 2009-04-14 Cytos Biotechnology Ag Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
CA2425648A1 (en) * 2000-10-19 2002-04-19 Epimmune Inc. Hla class i and ii binding peptides and their uses
US20030229906A1 (en) * 2002-04-15 2003-12-11 Gelman Irwin H. Methods and compositions for the treatment of disorders of HIV infection

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7476386B1 (en) * 1997-12-03 2009-01-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mixed lipopeptide micelles for inducing an immune response
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
US7517684B2 (en) * 1998-02-18 2009-04-14 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Pseudomonas aeruginosa for diagnostics and therapeutics
US7517520B2 (en) * 2003-03-26 2009-04-14 Cytos Biotechnology Ag Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Comparing pooled peptides with intact protein for accessing cross-presentation pathways for protective CD8+ and CD4+ T cells;HONGWEI ZHANG ET AL;《JOURNAL OF BIOLOGICAL CHEMISTRY》;20090403;第284卷(第14期);9184-9191 *
Intranasal administration of peptide antigens of HIV with mucosal adjuvant CpG ODN coentrapped in microparticles enhances the mucosal and systemic immune response;PUN P B ET AL;《INTERNATIONAL IMMUNOPHARMACOLOGY》;20090401;第9卷(第4期);468-477 *
Multiepitopic B-and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine;GAHERY-SEGARD H ET AL;《JOURNAL OF VIROLOGY》;20000201;第74卷(第4期);1694-1703 *

Also Published As

Publication number Publication date
US20140121170A2 (en) 2014-05-01
EP2440570A4 (en) 2012-04-18
WO2010144231A3 (en) 2011-04-21
US8551943B2 (en) 2013-10-08
EP2440570B1 (en) 2013-08-14
US8871708B2 (en) 2014-10-28
US20130018002A1 (en) 2013-01-17
WO2010144231A2 (en) 2010-12-16
US8563506B2 (en) 2013-10-22
US8476237B2 (en) 2013-07-02
JP2012529293A (ja) 2012-11-22
CN102482325A (zh) 2012-05-30
US8431530B2 (en) 2013-04-30
HK1167662A1 (en) 2012-12-07
US20130018003A1 (en) 2013-01-17
US20130123202A1 (en) 2013-05-16
US20100317566A1 (en) 2010-12-16
CA2761121A1 (en) 2010-12-16
EP2440570A2 (en) 2012-04-18
US20140005117A1 (en) 2014-01-02

Similar Documents

Publication Publication Date Title
CN102482325B (zh) 通过抑制微粒的分泌治疗aids或癌症的组合物和方法
KR20220123294A (ko) 폴리펩티드, 이의 제조방법 및 용도
Borghouts et al. Peptide aptamers: recent developments for cancer therapy
EP1379672A2 (en) Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (ptpc)
Chong et al. The MT hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance
US8685652B2 (en) Targets and compounds for therapeutic intervention of HIV infection
EP1012603B1 (en) Functional fragments of hiv-1 vpr protein and methods of using the same
US9163067B2 (en) HIV-1 integrase derived stimulatory peptides interfering with integrase—Rev protein binding
JP7057822B2 (ja) Ｈｉｖを強力に阻害するためのリポペプチド、その誘導体、その医薬組成物及びその使用
US20060210536A1 (en) Methods and compositions for inhibiting stat signaling pathways
CN106397548A (zh) 用于抑制hiv感染的多肽及其药物用途
HK1167662B (en) Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles
US20200115418A1 (en) Anti-hiv peptides
Muthumani et al. Anti-tumor activity mediated by protein and peptide transduction of HIV viral protein R (Vpr)
CA2407570A1 (en) Compositions and methods for delivery of a molecule into a cell
Huang et al. Interaction of HIV-1 gp41 core with NPF motif in Epsin: implication in endocytosis of HIV
US20060088551A1 (en) Functional fragments of HIV-1 VPR protein and methods of using the same
US20240190918A1 (en) Fibril peptides
Tamamura et al. Conjugated Compounds Involving Peptides
WO2014022947A1 (zh) 抑制hiv的短小多肽及药物用途
KR20080076614A (ko) Ｈⅰｖ ｎｃ 단백질을 포함하는 ａⅰｄｓ 예방 및 치료용조성물
Deshayes et al. Top Med Chem 8: 81-104
WO2016172524A1 (en) Compositions for inhibiting viral replication and methods of use and production thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1167662

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1167662

Country of ref document: HK